China
The China contagion that never was
Markets aren’t worried about China contagion – and you shouldn’t be, either.
Will NEUCA be taken over by the Chinese?
According to unofficial information from the authors, talks are underway about the acquisition of a controlling stake in Neuci by a consortium of Chinese companies, including Sinopharma.
The CSRC launched a series of policies tightening IPOs
2023年8月27日，在万众期待之下，证监会推出了一系列救市政策，包括降低印花税、IPO收紧、降低两融保证金、规范减持等多项内容。
The China Securities Regulatory Commission coordinates the balance of the primary and secondary markets and optimizes the regulatory arrangements for IPOs and refinancing
The China Securities Regulatory Commission (CSRC) announced on 27 August that the CSRC fully considers the current market situation, improves the counter-cyclical adjustment mechanism of the primary and secondary markets, and makes arrangements around reasonably grasping the rhythm of IPO and refinancing.
Pfizer Fights Claim It Fired Executive Who Raised Graft Concerns
Pfizer Inc. is fighting a lawsuit by a former employee who alleges he was fired after he raised concerns about the company paying tens of millions of dollars to government officials in China, where the drugmaker’s business practices have been under US review.
Biocytogen Announces Grand Opening of Waltham, MA Facility
Biocytogen Pharmaceuticals (HKEX: 02315; “Biocytogen”), a biotechnology company focused on the generation and validation of novel antibody-based therapeutics and specialized animal models for partners worldwide, today announces the grand opening of a new 37,000 sqft. facility in Waltham, MA for its US-based subsidiary, Biocytogen Boston Corporation.
United Imaging Healthcare delivers its 2023 Half-Year report, with revenue growth of 26.35% in the first half of 2023
United Imaging Healthcare (SSE:688271), a global innovator in cutting-edge medical imaging and radiotherapy equipment, has unveiled its highly anticipated 2023 half-year report, revealing robust growth.
Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today reported second quarter unaudited financial results for the period ended June 30, 2023, and provided corporate updates.
SINOVAC Reports Unaudited First Half of 2023 Financial Results
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2023.
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the second quarter ended June 30, 2023.
